These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38106909)

  • 21. Antimicrobial resistance in
    Senok A; Thomsen J; Abdulrazzaq NM; ; Menezes GA; Ayoub Moubareck C; Everett D
    Front Public Health; 2023; 11():1244357. PubMed ID: 38074724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immediate and later impacts of antimicrobial consumption on carbapenem-resistant Acinetobacter spp., Pseudomonas aeruginosa, and Klebsiella spp. in a teaching hospital in Brazil: a 10-year trend study.
    Federico MP; Furtado GH
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2153-2158. PubMed ID: 30112695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa.
    Tsao LH; Hsin CY; Liu HY; Chuang HC; Chen LY; Lee YJ
    J Microbiol Immunol Infect; 2018 Jun; 51(3):359-366. PubMed ID: 28988663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for hospitalized patients with resistant or multidrug-resistant
    Raman G; Avendano EE; Chan J; Merchant S; Puzniak L
    Antimicrob Resist Infect Control; 2018; 7():79. PubMed ID: 29997889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections.
    Lin KY; Lauderdale TL; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2016 Feb; 49(1):52-9. PubMed ID: 24662016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing Rates of Co-Resistance and Patient Outcomes in Multidrug-Resistant Pseudomonas aeruginosa.
    Appaneal HJ; Caffrey AR; Lopes V; Piehl EC; Puzniak LA; LaPlante KL
    Microbiol Spectr; 2022 Oct; 10(5):e0233622. PubMed ID: 36005836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Kresken M; Körber-Irrgang B; Korte-Berwanger M; Pfennigwerth N; Gatermann SG; Seifert H;
    Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections.
    Palavutitotai N; Jitmuang A; Tongsai S; Kiratisin P; Angkasekwinai N
    PLoS One; 2018; 13(2):e0193431. PubMed ID: 29470531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in
    Kang JS; Moon C; Mun SJ; Lee JE; Lee SO; Lee S; Lee SH
    J Korean Med Sci; 2021 Nov; 36(43):e273. PubMed ID: 34751008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic resistance, biofilm production ability and genetic diversity of carbapenem-resistant Pseudomonas aeruginosa strains isolated from nosocomial infections in southwestern Iran.
    Heidari R; Farajzadeh Sheikh A; Hashemzadeh M; Farshadzadeh Z; Salmanzadeh S; Saki M
    Mol Biol Rep; 2022 May; 49(5):3811-3822. PubMed ID: 35169997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacterial Epidemiology and Antimicrobial Resistance Profiles in Children Reported by the ISPED Program in China, 2016 to 2020.
    Fu P; Xu H; Jing C; Deng J; Wang H; Hua C; Chen Y; Chen X; Zhang T; Zhang H; Chen Y; Yang J; Lin A; Wang S; Cao Q; Wang X; Deng H; Cao S; Hao J; Gao W; Huang Y; Yu H; Wang C
    Microbiol Spectr; 2021 Dec; 9(3):e0028321. PubMed ID: 34730410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temporal trends and patterns in antimicrobial-resistant Gram-negative bacteria implicated in intensive care unit-acquired infections: A cohort-based surveillance study in Istanbul, Turkey.
    Durdu B; Kritsotakis EI; Lee ACK; Torun P; Hakyemez IN; Gultepe B; Aslan T
    J Glob Antimicrob Resist; 2018 Sep; 14():190-196. PubMed ID: 29751127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic Surveillance of Clinical Pseudomonas aeruginosa Isolates Reveals an Additive Effect of Carbapenemase Production on Carbapenem Resistance.
    Diorio-Toth L; Irum S; Potter RF; Wallace MA; Arslan M; Munir T; Andleeb S; Burnham CD; Dantas G
    Microbiol Spectr; 2022 Jun; 10(3):e0076622. PubMed ID: 35638817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular epidemiology and antibiotic resistance of
    Wang JZ; Dong XT; Zhang XN; Deng P; Cheng F; Ma WS
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1558-1564. PubMed ID: 37859371
    [No Abstract]   [Full Text] [Related]  

  • 35. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
    Marner M; Kolberg L; Horst J; Böhringer N; Hübner J; Kresna IDM; Liu Y; Mettal U; Wang L; Meyer-Bühn M; Mihajlovic S; Kappler M; Schäberle TF; von Both U
    Microbiol Spectr; 2023 Feb; 11(1):e0443722. PubMed ID: 36692293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chinese expert consensus on the management of lower respiratory tract infections of
    Pulmonary Infection Assembly of Chinese Thoracic Society
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):739-752. PubMed ID: 35927044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients.
    Peña C; Gómez-Zorrilla S; Suarez C; Dominguez MA; Tubau F; Arch O; Oliver A; Pujol M; Ariza J
    Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2791-7. PubMed ID: 22552893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
    Borgatta B; Gattarello S; Mazo CA; Imbiscuso AT; Larrosa MN; Lujàn M; Rello J
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2155-2163. PubMed ID: 28624864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.